Levetiracetam treatment leads to functional recovery after thoracic or cervical injuries of the spinal cord

• Published in: npj Regenerative medicine 2021-03, Vol.6 (1), p.11-11, Article 11
• Main Authors: Lima, Rui, Gomes, Eduardo D., Cibrão, Jorge R., Rocha, Luís A., Assunção-Silva, Rita C., Rodrigues, Cláudia S., Neves-Carvalho, Andreia, Monteiro, Susana, Salgado, António J., Silva, Nuno A.
• Format: Article
• Language: English
• Subjects: 631/378/1687; 631/378/1687/1825; Biomaterials; Biomedical and Life Sciences; Biomedicine; Cell Biology; Immunology; Regenerative Medicine/Tissue Engineering; Spinal cord; Stem Cells
• ISSN: 2057-3995; 2057-3995
• DOI: 10.1038/s41536-021-00121-7

Spinal cord injury (SCI) leads to dramatic impairments of motor, sensory, and autonomic functions of affected individuals. Following the primary injury, there is an increased release of glutamate that leads to excitotoxicity and further neuronal death. Therefore, modulating glutamate excitotoxicity seems to be a promising target to promote neuroprotection during the acute phase of the injury. In this study, we evaluated the therapeutic effect of a FDA approved antiepileptic drug (levetiracetam-LEV), known for binding to the synaptic vesicle protein SV2A in the brain and spinal cord. LEV therapy was tested in two models of SCI—one affecting the cervical and other the thoracic level of the spinal cord. The treatment was effective on both SCI models. Treated animals presented significant improvements on gross and fine motor functions. The histological assessment revealed a significant decrease of cavity size, as well as higher neuronal and oligodendrocyte survival on treated animals. Molecular analysis revealed that LEV acts by stabilizing the astrocytes allowing an effective uptake of the excess glutamate from the extracellular space. Overall, our results demonstrate that Levetiracetam may be a promising drug for acute management of SCI.